Pancreatic adenocarcinoma: Molecular drivers and the role of targeted therapy
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …
many efforts channeled to improve its management. Although the mainstay treatment is still …
Pancreatic cancer: new approaches to drug therapy
VJ Picozzi - International Journal of Surgery, 2024 - journals.lww.com
Outcomes in pancreatic ductal adenocarcinoma (PDAC) remain poor due to a variety of
biological, clinical, and societal factors. However, in recent years, PDAC has seen 1) …
biological, clinical, and societal factors. However, in recent years, PDAC has seen 1) …
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
M Chiaravalli, M Reni, EM O'Reilly - Cancer treatment reviews, 2017 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy with an overall 5-year
survival of 8% for all stages combined. The majority of patients present with stage IV disease …
survival of 8% for all stages combined. The majority of patients present with stage IV disease …
Pancreatic cancer: progress in systemic therapy
L Perkhofer, TJ Ettrich, T Seufferlein - Gastrointestinal Tumors, 2015 - karger.com
Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-
related deaths in the Western world. Due to lack of specific symptoms and no accessible …
related deaths in the Western world. Due to lack of specific symptoms and no accessible …
[HTML][HTML] Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of death in
the United States and is expected to be ranked second in the next 10 years due to poor …
the United States and is expected to be ranked second in the next 10 years due to poor …
[HTML][HTML] Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review
SM Ruff, TM Pawlik - Frontiers in Bioscience-Landmark, 2024 - imrpress.com
Pancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many
patients with PDAC present with late-stage disease and even early-stage disease can often …
patients with PDAC present with late-stage disease and even early-stage disease can often …
New therapeutic targets in pancreatic cancer
E Lai, M Puzzoni, P Ziranu, A Pretta, V Impera… - Cancer treatment …, 2019 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly
diagnosed patients, only about 20% can benefit from a potentially curative surgical …
diagnosed patients, only about 20% can benefit from a potentially curative surgical …
[HTML][HTML] Perspectives in the treatment of pancreatic adenocarcinoma
A Cid-Arregui, V Juarez - World journal of gastroenterology: WJG, 2015 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is an incurable lethal disease whose incidence
rate is growing. There is no effective screening for detection of early stage tumors and, in …
rate is growing. There is no effective screening for detection of early stage tumors and, in …
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma
M Sardar, A Recio-Boiles, K Mody… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy projected to
be the 2nd leading cause of cancer related death in the USA by 2030. This manuscript …
be the 2nd leading cause of cancer related death in the USA by 2030. This manuscript …
Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …